Clinical assessment of glutathione peroxidase and catalase to the status of malondialdehyde in urolithiasis

To assess the role of lipid peroxidation and antioxidant enzymes in serum of urolithiasis patients. Glutathione peroxidase [GPx], catalase [CAT] and malondialadehyde [MDA] in serum of urolithiasis patients have been measured. The study has revealed a significant increase in MDA and a significant decrease in GPx and CAT. There have been no significant correlations of serum MDA, GPx and CAT to the size and number of stones with no differences in their levels among patients with one stone, two stones and multiple stones. Anatomically the distributions of urinary stones have been 70.14% renal, 19.30% uretric and 3.15% urinary bladder. There have been no significant difference in serum levels of neither MDA nor CAT among all the anatomical sites of the stone, while GPx has shown a significant difference in serum of patients with renal calyceal, renal pelvic, ureteric and vesical stones. Patients with recurrent episode of urinary stone have been 63.33%. Family histories of urolithiais have been negative in 73.33% of the patients. Neither recurrence of urinary stone nor family history of urolithiasis have shown a significant correlation with serum levels of MDA, GPx and CAT. The role of lipid peroxidation and antioxidant enzymes is present in the pathogenesis of urinary stone, but their levels don't affect by the size, the number and the anatomical position of stones [apart of GPx which has been affected by the anatomical position of the stone] and the duration, recurrence, and family history of the disease

Alteraciones en la actividad del calcio-magnesio ATPasa en la membrana de los eritrocitos en pacientes litiasicos con hipercalciuria / Alterations in the calcium-magnesium activity ATPase in the membrane of the erytrosites in lithiasic patients with hypercalciuria

La CaMgATPasa es una enzima involucrada en los movimientos de calcio a través de las membranas biológicas. Nosotros testeamos la actividad de dicha enzima en membranas de eritrocitos de 17 pacientes hipercalciúricos y la comparamos con 8 controles sanos. Los pacientes con hipercalciuria tuvieron una actividad de CaMgATPasa que fue significativamente superior a los controles (18,02 2,83 vs 14,69 1,78 nM . mg-1 p<0,01). La excreción de urinaria de calcio en 24 hs (UCa.V) estuvo directa y significativamente relacionada con la actividad de la enzima (UCa.V: 36,31 x CaMgATPasa - 371,08 r:0,65 p<0,05) sólo en pacientes con hipercalciuria. Cuando agrupamos los pacientes acorde al diagnóstico fisiopatológico en hipercalciuria absortiva (HCA) e hipercalciuria renal (HCRT) encontramos que la actividad enzimática estuvo sólo significativamente elevada en aquellos portadores de HCA al compararlos con los controles (19,17 3,49 vs 14,68 1,79 nM . mg-1 .min-1 p<0,025).No encontramos diferencias estadísticamente significativas entre HCRT y controles (16,83 1,99nM . mg-1 . min-1; p:NS) y en HCRT vs HCA (p<0,14). Concluimos que las alteraciones en el transporte de calcio en la hipercalciuria dependería de anormalidades en la actividad de la CaMgATPasa